Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly ...

Workplace stress, long hours, and unhealthy habits are raising diabetes risk among India’s young professionals. Awareness and ...

New analyses of an investigational high-dose semaglutide pill for obesity showed improvements in blood sugar control and ...

While drugs like Wegovy, Ozempic and Mounjaro are hailed for regulating blood sugar and helping people lose weight, new ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.

An apple a day keeps the doctor away, or so the old proverb says. But, is there any truth to it? Apples are both affordable ...

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...

GLP-1 drugs like Ozempic are reshaping obesity care, blending real weight loss gains with new questions about safety, access, ...

A new University College London study featuring 17,604 participants age 45 and up discovered that semaglutide -- a GLP-1 agonist found in weight-loss drugs like Ozempic and Wegovy -- decreases the ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...